Release Date: 11-Feb-2025
In 2024, Imdelltra, a DLL3 andtimes; CD3 bispecific antibody for extensive-stage small cell lung cancer (ES-SCLC), achieved sales of US$ 115 million following its approval in May 2024. Despite being a newly launched therapy, it has quickly gained traction, reflecting strong market demand and clinician adoption. Its early commercial success highlights the growing interest in bispecific antibodies for hard-to-treat cancers. Imdelltra’s performance underscores the potential for targeted immunotherapies in lung cancer, positioning it as a key player in the expanding bispecific antibody market and reinforcing the trend of novel biologics driving revenue growth in oncology.
In 2024, Imdelltra achieved sales of US$ 115 million following its approval in May 2024, marking a strong commercial debut. As the first and only DLL3-targeting therapy on the market, it has quickly gained traction in the treatment of extensive-stage small cell lung cancer (ES-SCLC). This first-in-class DLL3 andtimes; CD3 bispecific antibody has been met with significant demand, reflecting the growing need for novel immunotherapies in lung cancer. Imdelltra’s rapid uptake highlights its potential in the bispecific antibody space, reinforcing the expanding role of targeted biologics in oncology and paving the way for future DLL3-targeted treatments.
For Global Bispecific Antibodies Report Sample Contact [email protected]